A Trial of Same-Day Testing and Treatment to Improve Outcomes Among Symptomatic Patients Newly Diagnosed With HIV
調査の概要
詳細な説明
This study is a randomized trial that will compare outcomes with standard and same-day treatment among patients with TB symptoms at HIV diagnosis. The standard group will receive same-day chest x-ray as well as Xpert Ultra testing with a spot specimen (with 48-hour turn-around-time). Participants will return for Xpert Ultra results and early morning sputum testing on Day 2. TB treatment will be provided on the day of diagnosis (Day 0 for those with high clinical and radiographic suspicion of TB, and Day 2 for those diagnosed by spot Xpert Ultra). Standard group participants who are not diagnosed with TB will be tested and treated for other opportunistic infections (OIs), as clinically indicated, and will initiate ART on Day 7. The same-day group will receive Xpert Ultra testing (with same-day results) and chest x-ray with same-day ART or TB treatment (on Day 0) based on test results. They will also be tested and treated for other OIs as clinically indicated. They will provide early morning sputum for repeat testing on Day 1. Both groups will receive Xpert Ultra testing on both spot and early morning specimens, with liquid culture on both specimens as the diagnostic gold standard; those with TB will start ART according to WHO guidelines.
Three specific aims are proposed:
Aim 1: To compare the proportion of participants in each group who are alive and in care with undetectable viral load (<200 copies/ml) at 48 weeks after HIV testing. Hypothesis: The proportion of participants retained in care with undetectable viral load will be 51% in the standard and 65% in the same-day group.
Aim 2: To compare mortality in each group at 48 weeks after HIV testing. Hypothesis: Mortality will be 10% in the standard group and 4% in the same-day group.
Aim 3: To conduct a comparison of cost and cost-effectiveness of standard and same-day care, where cost is measured by the mean treatment cost and effectiveness is measured by being alive and in care with plasma HIV-1 RNA level <200 copies/ml at 48 weeks after HIV testing. Hypothesis: Same-day treatment will cost less per patient retained in care with undetectable viral load.
Aim 4: To determine the rates of ART and TB treatment initiation, TB diagnosis after ART initiation, IRIS, adverse events, and adherence in both groups, and to evaluate the sensitivity, specificity, and predictive values of single tests and different testing combinations compared to liquid mycobacterial culture results.
研究の種類
入学 (実際)
段階
- 適用できない
連絡先と場所
研究場所
-
-
-
Port-au-Prince、ハイチ
- GHESKIO
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Men and women of ≥18 years of age
- Presence of cough, fever, night sweats or weight loss
- Ability and willingness to give written informed consent
- Documentation of positive HIV status (test conducted at GHESKIO)
- Acceptance of HIV diagnosis, defined as affirmative responses to two questions: "I believe that HIV and AIDS exist" and "I believe that the results of my HIV test show that I am infected".
Exclusion Criteria:
- Any use of ART in the past
- Treatment for TB in the year prior to screening visit
- Pregnancy or breastfeeding at the screening visit
- Active drug, alcohol use, or mental condition that would interfere with the ability to adhere to study requirements, in the opinion of the study physician
- Score of <3 for any of the 7 questions on the ART readiness survey
- Planning to transfer care to another clinic during the study period
- Symptoms consistent with WHO stage 4 neurologic disease (cryptococcal meningitis, TB meningitis; central nervous system toxoplasmosis; HIV encephalopathy; progressive multifocal leukoencephalopathy)
- Severe illness, classified as one of the WHO "danger signs" of temperature >39 degrees Celsius, pulse >120 beats/minutes, respiratory rate >30, or inability to walk unaided.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
---|---|
アクティブコンパレータ:Standard Group
On Day 0 (day of HIV diagnosis and study enrollment) participants will receive a chest x-ray and provide a sputum specimen for spot Xpert Ultra testing (48-hour results).
Those with high clinical/radiographic suspicion for TB will start same-day TB treatment.
On Day 2, participants will return for results of Xpert Ultra testing (spot specimen) and to provide a specimen for early morning Xpert Ultra testing.
Those who are Xpert Ultra positive will start TB treatment.
Those who are not diagnosed with TB will start ART on Day 7, after testing and treatment for other opportunistic infections.
A liquid TB culture will be performed on both the spot and early morning specimens.
|
標準治療
|
実験的:Same-Day Treatment Group
On Day 0 (day of HIV diagnosis and study enrollment) participants will receive a chest x-ray and Xpert Ultra testing with same-day results.
Based on clinical symptoms, Xpert Ultra results, and chest x-ray, physician will determine whether or not the participant has tuberculosis.
Those who are diagnosed with TB will start same-day TB treatment.
Those who are not diagnosed with TB will start same-day ART.
|
Treatment with ART or TB medication on day of HIV diagnosis
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
Retention in care with viral suppression
時間枠:48 weeks after HIV testing
|
Proportion of participants who are in care with HIV-1 RNA <200 copies/ml
|
48 weeks after HIV testing
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
Mortality
時間枠:48 weeks after HIV testing
|
All-cause mortality
|
48 weeks after HIV testing
|
Mean treatment cost per participant
時間枠:48 weeks after HIV testing
|
Mean treatment cost per participant
|
48 weeks after HIV testing
|
Viral suppression
時間枠:48 weeks after HIV testing
|
Proportion of participants with HIV-1 RNA <50 copies/ml and <1000 copies/ml
|
48 weeks after HIV testing
|
Adherence by medication possession ratio
時間枠:48 weeks after HIV testing
|
Proportion of participants with 48-week adherence to ART of at least 90% by pharmacy refill records
|
48 weeks after HIV testing
|
Adherence by 3-day self-report
時間枠:48 weeks after HIV testing
|
Proportion of participants with perfect (100%) adherence as measured by 3-day self-report at 48 weeks after HIV testing
|
48 weeks after HIV testing
|
Treatment failure
時間枠:48 weeks
|
Proportion of participants meeting WHO criteria for ART failure and proportion initiating second-line ART during the study period
|
48 weeks
|
TB testing characteristics
時間枠:These diagnostic tests will be conducted during the first week of study enrollment
|
Sensitivity, specificity, predictive values, and likelihood ratios of spot and early morning Xpert Ultra results and chest x-ray, as single and as combined tests, with liquid culture as gold standard
|
These diagnostic tests will be conducted during the first week of study enrollment
|
Time in clinic
時間枠:First study day and first study month
|
Median time spent in clinic during first day and month of the study
|
First study day and first study month
|
Coping with HIV diagnosis
時間枠:2 Weeks, 12 Weeks, 24 Weeks, and 48 Weeks after HIV Testing
|
Scores on the COPE survey
|
2 Weeks, 12 Weeks, 24 Weeks, and 48 Weeks after HIV Testing
|
Connectedness to Treatment Setting
時間枠:2 Weeks, 12 Weeks, 24 Weeks, and 48 Weeks after HIV Testing
|
Scores on the Connectedness to Treatment Setting Scale
|
2 Weeks, 12 Weeks, 24 Weeks, and 48 Weeks after HIV Testing
|
TB diagnosis after ART initiation
時間枠:48-week study period
|
Diagnosis of culture-positive TB after ART initiation (BACTEC MGIT 960, Becton Dickinson)
|
48-week study period
|
Incidence of immune reconstitution inflammatory syndrome (IRIS)
時間枠:48-week study period
|
Incidence of paradoxical or unmasking IRIS
|
48-week study period
|
Adverse events
時間枠:48-week study period
|
New Division of AIDS Grade 3 or Grade 4 signs, symptoms, or laboratory abnormalities that are at least a one-grade increase from baseline
|
48-week study period
|
Measure of hope and optimism
時間枠:2 Weeks, 12 Weeks, 24 Weeks, and 48 Weeks after HIV Testing
|
Scores on the State Hope Scale
|
2 Weeks, 12 Weeks, 24 Weeks, and 48 Weeks after HIV Testing
|
Patient satisfaction
時間枠:12 Weeks, 24 Weeks, and 48 Weeks after HIV Testing
|
Scores on the HRSA Patient Satisfaction Survey
|
12 Weeks, 24 Weeks, and 48 Weeks after HIV Testing
|
Time to death
時間枠:48-week study period
|
Days to death
|
48-week study period
|
Last missed dose of medication
時間枠:2 Weeks, 12 Weeks, 24 Weeks, 48 Weeks
|
Proportion of participants who report last missed dose of ART was at least 2 weeks ago
|
2 Weeks, 12 Weeks, 24 Weeks, 48 Weeks
|
協力者と研究者
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- AI131998
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。
HIV/エイズの臨床試験
-
Massachusetts General HospitalNational Institute of Allergy and Infectious Diseases (NIAID); Emory University; University of... と他の協力者完了
-
University of California, San Diego完了
-
University of California, San DiegoJanssen Research & Development, LLC完了
-
Elizabeth Glaser Pediatric AIDS FoundationPopulation Council; Ministry of Health, Tanzania完了
-
Medical College of WisconsinNational Institute of Mental Health (NIMH)完了
-
Centers for Disease Control and PreventionJohns Hopkins University; Columbia University; University of Pittsburgh; RTI International; US Department...完了HIV | AIDS
-
Kristine Patterson, MDMerck Sharp & Dohme LLC完了
-
University of California, San DiegoNational Institute of Allergy and Infectious Diseases (NIAID)完了
標準治療の臨床試験
-
University of Oxford完了
-
Medical University of South CarolinaIcahn School of Medicine at Mount Sinai完了
-
Washington State UniversityNational Institute on Drug Abuse (NIDA)完了
-
Rigshospitalet, DenmarkTestcenter Danmark, Statens Serum Institut; Copenhagen Emergency Medical Services完了
-
Reistone Biopharma Company Limited完了
-
Compedica IncProfessional Education and Research Institute募集